Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity

被引:10
|
作者
van Tilburg, Cornelis M. [1 ]
Sanders, Elisabeth A. M. [2 ]
Nibbelke, Elisabeth E. [1 ]
Pieters, Rob [3 ,6 ]
Revesz, Tom [4 ]
Westers, Paul [5 ]
Wolfs, Tom F. W. [2 ]
Bierings, Marc B. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Paediat Haematol Oncol, NL-3508 AB Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Paediat Immunol & Infect Dis, NL-3508 AB Utrecht, Netherlands
[3] Dutch Childhood Oncol Grp, The Hague, Netherlands
[4] SA Pathol Womens & Childrens Hosp, Haematol Oncol Dept, Adelaide, SA, Australia
[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[6] Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol Haematol, Rotterdam, Netherlands
关键词
acute lymphoblastic leukaemia; infection; chemotherapy; child; toxicity; MINIMAL RESIDUAL DISEASE; AIEOP-BFM; CHILDREN; CANCER; THERAPY;
D O I
10.1111/j.1365-2141.2010.08463.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Reducing infectious morbidity is an important goal to improve childhood acute lymphoblastic leukaemia (ALL) survival. To explore the impact of chemotherapy reduction on infectious morbidity, we compared outpatient and inpatient infectious morbidity of reduced versus intensive (conventional) chemotherapy. One hundred and seventy-one children newly diagnosed with ALL between 2004 and 2007 and treated according to the Dutch Childhood Oncology Group ALL 10 protocol were prospectively followed during the 2-year treatment course. Stratified by minimal residual disease, 54 patients received reduced (standard risk; SR) and 117 patients received intensive (medium risk; MR) intensification/maintenance treatment. SR outpatients had a median of 1 febrile episode versus 4 in MR outpatients (P = 0 center dot 002). SR patients had fewer hospitalizations for fever. They were admitted a median of 0 times, with a median of 0 days of hospitalization, median 0 days of fever, median 0 times chemotherapy interruption and median 0 times intravenous antibiotics. MR patients were admitted for fever median 2 times (P < 0 center dot 001) with 10 days of hospitalization (P < 0 center dot 001), 2 days of fever (P < 0 center dot 001), one chemotherapy interruption (P < 0 center dot 001) and two intravenous antibiotics administration (P < 0 center dot 001). These data indicate that reduced intensification/maintenance compared to conventional intensive intensification/maintenance chemotherapy for good risk childhood ALL resulted in major decrease of infectious morbidity.
引用
收藏
页码:433 / 440
页数:8
相关论文
共 50 条
  • [1] Risk Factors for Treatment Related Mortality in Childhood Acute Lymphoblastic Leukaemia
    Lund, Bendik
    Asberg, Ann
    Heyman, Mats
    Kanerva, Jukka
    Harila-Saari, Arja
    Hasle, Henrik
    Soderhall, Stefan
    Jonsson, Olafur Gisli
    Lydersen, Stian
    Schmiegelow, Kjeld
    PEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 551 - 559
  • [2] Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia
    Lund, Bendik
    Wesolowska-Andersen, Agata
    Lausen, Birgitte
    Borst, Louise
    Rasmussen, Kirsten Korup
    Muller, Klaus
    Klungland, Helge
    Gupta, Ramneek
    Schmiegelow, Kjeld
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (04) : 321 - 330
  • [3] Breastfeeding patterns and risk of childhood acute lymphoblastic leukaemia
    Kwan, ML
    Buffler, PA
    Wiemels, JL
    Metayer, C
    Selvin, S
    Ducore, JM
    Block, G
    BRITISH JOURNAL OF CANCER, 2005, 93 (03) : 379 - 384
  • [4] Breastfeeding patterns and risk of childhood acute lymphoblastic leukaemia
    M L Kwan
    P A Buffler
    J L Wiemels
    C Metayer
    S Selvin
    J M Ducore
    G Block
    British Journal of Cancer, 2005, 93 : 379 - 384
  • [5] The combination of bortezomib with chemotherapy to treatrelapsed/refractory acute lymphoblastic leukaemia of childhood
    Bertaina, Alice
    Vinti, Luciana
    Strocchio, Luisa
    Gaspari, Stefania
    Caruso, Roberta
    Algeri, Mattia
    Coletti, Valentina
    Gurnari, Carmelo
    Romano, Mariateresa
    Cefalo, Maria Giuseppina
    Girardi, Katia
    Trevisan, Valentina
    Bertaina, Valentina
    Merli, Pietro
    Locatelli, Franco
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (04) : 629 - 636
  • [6] The changing landscape of treatment options in childhood acute lymphoblastic leukaemia
    Micallef, Benjamin
    Nistico, Robert
    Sarac, Sinan B.
    Bjerrum, Ole W.
    Butler, Dianne
    Bartolo, Nicolette Sammut
    Serracino-Inglott, Anthony
    Borg, John Joseph
    DRUG DISCOVERY TODAY, 2022, 27 (05) : 1483 - 1494
  • [7] Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: Impact on lymphocyte compartment composition
    van Tilburg, Cornelis M.
    van der Velden, Vincent H. J.
    Sanders, Elisabeth A. M.
    Wolfs, Tom F. W.
    Gaiser, Jacobus F.
    de Haas, Valerie
    Pieters, Rob
    Bloem, Andries C.
    Bierings, Marc B.
    LEUKEMIA RESEARCH, 2011, 35 (04) : 484 - 491
  • [8] Predicting relapse risk in childhood acute lymphoblastic leukaemia
    Teachey, David T.
    Hunger, Stephen P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) : 606 - 620
  • [9] Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood
    Rae, C.
    Furlong, W.
    Jankovic, M.
    Moghrabi, Albert
    Naqvi, A.
    Sala, A.
    Samson, Y.
    Depauw, S.
    Feeny, D.
    Barr, R.
    EUROPEAN JOURNAL OF CANCER CARE, 2014, 23 (06) : 779 - 785
  • [10] Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review
    Donadieu, J
    Hill, C
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) : 34 - 45